Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;24(10):503-513.
doi: 10.1007/s11940-022-00733-4. Epub 2022 Jul 30.

Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?

Ammad Mahmood  1 , Keith W Muir  1   2
Affiliations
Review

Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?

Ammad Mahmood et al. Curr Treat Options Neurol. 2022.

Abstract

Purpose of review: Alteplase has been the thrombolytic of choice for acute ischaemic stroke for more than two decades. A thrombolytic which is easier to administer and with improved or comparable safety and efficacy is desirable. Tenecteplase has emerged as a potential successor, and its off-license use in acute ischaemic stroke has increased in recent years. We aimed to examine the evidence base for each drug and discuss their use in varying patient populations in acute ischaemic stroke.

Recent findings: Several trials comparing tenecteplase and alteplase have reported very recently with the results of the ACT trial strengthening the argument in favour of non-inferiority of tenecteplase to alteplase. Ongoing trials such as ATTEST-2 are of interest, and trials such as TASTE and TEMPO-2 will shed further light on use of tenecteplase in specific populations.

Summary: A single thrombolytic agent for all indications for thrombolysis in acute ischaemic stroke is desirable in streamlining workflows. Based on recent and upcoming trials, guidelines may soon recommend tenecteplase as a suitable alternative to alteplase. The use of tenecteplase in specific subgroups will depend on further recruitment to ongoing clinical trials.

Keywords: Acute ischaemic stroke; Alteplase; Tenecteplase; Thrombolysis.

PubMed Disclaimer

References

    1. Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Neurology. 2021;20(10):795–820. doi: 10.1016/S1474-4422(21)00252-0. - DOI - PMC - PubMed
    1. Berge E, Whiteley W, Audebert H, De Marchis GM, Fonseca AC, Padiglioni C, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. European stroke journal. 2021;6(1):I-LXII. - PMC - PubMed
    1. NINDS. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med. 1995;333(24):1581–8. - PubMed
    1. Bivard A, Lin L, Parsons MW. Review of stroke thrombolytics. J Stroke. 2013;15(2):90–98. doi: 10.5853/jos.2013.15.2.90. - DOI - PMC - PubMed
    1. Brown SG, Macdonald SP, Hankey GJ. Do risks outweigh benefits in thrombolysis for stroke? BMJ. 2013;347:f5215. doi: 10.1136/bmj.f5215. - DOI - PubMed